With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. The transaction is part ...

CTC PD-L1 assay enables longitudinal monitoring of PD-L1 status in lung cancer patients and may help to advance personalised treatment GUILDFORD, UNITED KINGDOM / ACCESSWIRE / November 15, 2024 / ...

Non-small cell lung cancer (NSCLC) remains a predominant cause of cancer-related mortality worldwide. In recent years, immune checkpoint inhibitors (ICIs) have emerged as a transformative therapeutic ...

TD Cowen analyst Marc Frahm maintained a Buy rating on Shattuck Labs (STTK – Research Report) yesterday. The company’s shares ...

Third Quarter 2024 Financial Results Collaboration revenue increased by $1.2 million to $3.3 million for the three months ended September 30, 2024, from $2.1 million for the three months ended ...

As of September 30, 2024, Fortress' consolidated cash and cash equivalents totaled $58.9 million, compared to $76.2 million ...

Checkpoint Therapeutics' cosibelimab shows strong efficacy in treating cSCC. Learn why CKPT stock could see significant gains ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

Researchers from Auburn University, partnering with the University of Basel in Switzerland, have discovered a new way to make ...

During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old ...

Auburn, AL - Researchers from Auburn University, partnering with the University of Basel in Switzerland, have discovered a ...